drugset / Trial / NCT00337376
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Rapamycin is a drug that has been approved by the Food and Drug Administration (government) for use in patients receiving a kidney transplant to prevent the patient's body from rejecting the transplanted kidney. It has shown antitumor effects in the laboratory, but has not been approved at this time for the treatment of cancer. Abraxane is a new form of chemotherapy that has been approved by the Food and Drug Administration for the treatment of metastatic breast cancer, and is a promising drug that is being evaluated in clinical trials for treatment of other cancers. This is a phase I study designed to find out if different doses of Rapamycin, when combined with Abraxane, are safe and well tolerated.
Timeline
- Start
- 2006-02
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 5 mg | Oral |
| Subject | Sirolimus | Small molecule | 10 mg | Oral |
| Subject | Sirolimus | Small molecule | 20 mg | Oral |
| Subject | Sirolimus | Small molecule | 40 mg | Oral |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
Indications
No indication recorded.